Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured US Medicare reimbursement eligibility for eligible procedures ...
Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical ...
Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in ...
Clinical Trials Arena on MSN
Paradigm Health debuts post-marketing study tool for routine care integration
SPIRE is designed to allow more routine care providers in community and rural settings to participate in post-marketing ...
Paradigm Health today announced SPIRE -- Scalable Platform for Integrated Research & Evidence -- a new model for post-approval and late-stage clinical studies designed to help sponsors generate ...
COLUMBUS, Ohio and NEW YORK, April 8, 2026 /PRNewswire/ -- New peer-reviewed research demonstrates the feasibility and effectiveness of Paradigm Health's EHR-integrated eSource platform to support ...
The proposed DurAVR ® THV global pivotal registration trial has been formally designated as the PARADIGM Trial, signifying the trial’s central role in the DurAVR ® THV Clinical Development Program. An ...
The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower ...
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...
Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR), a global structural heart company committed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results